Blinatumomab versus chemotherapy in pediatric B-ALL: A meta-analysis of randomized trials in relapsed and high-risk frontline disease.
Adeena Musheer, Muhammad Shaheer Mannan, Muhammad Waqas Khan et al.
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis evaluated the efficacy of blinatumomab compared to chemotherapy in pediatric patients with relapsed/refractory or high-risk frontline B-cell acute lymphoblastic leukemia (B-ALL). Involving 2,011 patients from four randomized controlled trials, the study found that blinatumomab significantly improved disease-free survival (DFS) and overall survival (OS) with risk ratios of 0.63 and 0.62, respectively.
Key findings
- Blinatumomab improved disease-free survival (DFS) with a risk ratio of 0.63.
- Overall survival (OS) was significantly better with blinatumomab, risk ratio 0.62.
- No significant improvement in MRD clearance was observed (RR: 1.21).
- Adverse event rates were similar between blinatumomab and chemotherapy groups.
Why it matters
The findings indicate that blinatumomab may enhance survival outcomes in pediatric patients with high-risk B-ALL, which is crucial given the high relapse rates associated with this disease. Understanding these benefits can guide treatment decisions in this vulnerable population.